Core Viewpoint - Codexis, Inc. will report its financial results for Q3 2025 on November 6, 2025, and will host a conference call to discuss these results and provide a business update [1]. Company Overview - Codexis is a leading provider of enzymatic solutions aimed at efficient and scalable manufacturing of complex therapeutics, utilizing its proprietary CodeEvolver technology platform [3]. - The company is developing the ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route [3]. - Codexis' enzymes are designed to address challenges in small molecule pharmaceuticals manufacturing and nucleic acid synthesis, offering benefits such as higher yields, reduced energy usage, and improved efficiency [3].

Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop and enhance novel, high- performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeuti ...

Core Insights - Codexis will present data demonstrating the scalability and reproducibility of its enzymatic siRNA manufacturing processes at the TIDES USA annual meeting from May 19-22, 2025 [1][8] - The company will host two oral presentations and one poster presentation, focusing on various aspects of siRNA manufacturing [1][3][4] - A conference call is scheduled for May 22, 2025, to discuss the data presented during the conference [1][5] Presentation Details - The main stage talk will cover "Oligonucleotide CMC for Sustainable and Scalable Enzymatic siRNA Manufacturing" on May 21, 2025, by Alison Moore, PhD [3] - A comparative analysis of diastereomeric distribution in siRNA synthesis will also be presented by Stephanie Forget, PhD, on the same day [3] - A co-presentation with Bachem will focus on "Efficient Large-scale siRNA Manufacturing: Enzymatic Ligation of Short RNA Fragments" on May 20, 2025 [4] Poster Presentation - The poster titled "Machine Learning-Guided Ligation Fragment Design for Efficient siRNA Synthesis" will be presented by Mathew Miller, PhD, throughout the conference duration [5] Technological Advancements - Codexis is developing its proprietary ECO Synthesis™ manufacturing platform aimed at enabling the scaled manufacture of RNAi therapeutics through enzymatic methods [8] - The company is leveraging a groundbreaking machine learning tool to optimize ligase selection and fragment design, enhancing the efficiency of its manufacturing processes [6][8]

Core Viewpoint - Codexis, Inc. will report its financial results for Q1 2025 on May 14, 2025, and will host a conference call to discuss these results and provide a business update [1]. Company Overview - Codexis is a leading provider of enzymatic solutions aimed at efficient and scalable therapeutics manufacturing, utilizing its proprietary CodeEvolver technology platform to enhance high-performance enzymes [3]. - The company is developing the ECO Synthesis™ manufacturing platform to facilitate the scaled production of RNAi therapeutics through an enzymatic process [3]. - Codexis enzymes are designed to address challenges in small molecule pharmaceuticals manufacturing and nucleic acid synthesis, offering benefits such as higher yields, reduced energy consumption, and improved efficiency in manufacturing [3].